



NAoMe Newsletter, February 2024

Highlights

- 1** Scoping Document published
- 2** COSD Roadshows Jan & Feb 2024
- 3** Patient & Public Involvement Forum recruitment

NAoMe Scoping Document November 2023 - Executive Summary

The National Audit of Metastatic Breast Cancer (NAoMe) aims to report on patients diagnosed with metastatic breast cancer (MBC) who have been diagnosed, treated or managed in the UK (England, Wales, Northern Ireland, Scotland and Gibraltar) in 2023. The audit will focus on the quality of care and outcomes for these patients, with a particular emphasis on the use of systemic therapies and the management of symptoms and quality of life.

The information below is a summary of the main findings from the scoping document. For further details for the aspects covered below, please refer to the full published document available via <https://www.nao-me.org.uk/scoping-document>.

Metastatic breast cancer (MBC)

- Is a type of breast cancer that has spread from the breast to other parts of the body.
- It is typically diagnosed after a breast lump has been found, or after a breast lump has been found to be suspicious on imaging or other investigations.
- It is the most common type of breast cancer, with around 10,000 new diagnoses each year in the UK.
- It is a complex disease, with many different types and subtypes.
- It is a long-term condition, with many patients living for several years after diagnosis.
- It is a life-threatening condition, with many patients dying from the disease.

How has the scope of the NAoMe been developed?

- Review of the wider literature (including generalist and specialist journals).
- Consultation with stakeholders on an opinion for the NAoMe on the scope of the audit.
- Review of the NAoMe on the scope of the audit.

How has the NAoMe engaged with stakeholders so far?

- Stakeholder meetings with clinicians & patients at an initial NAoMe forum in London in February 2023.
- Stakeholder meetings with clinicians & patients at an initial NAoMe forum in London in February 2023.
- Stakeholder meetings with clinicians & patients at an initial NAoMe forum in London in February 2023.

What did we find from the scoping survey response?

- 539 survey responses for NAoMe questions including 256 potential patient records, 77 survey responses, 77 responses.
- Survey responses highlighted the need for:
 - Improved data collection
 - Improved data collection
 - Improved data collection

What patients will the NAoMe include?

- All patients (primary and secondary) with a confirmed diagnosis of metastatic breast cancer (MBC) who are registered with a GP in England, Wales, Northern Ireland, Scotland and Gibraltar.
- Diagnosed in an NHS hospital in England and Wales.

What data will the audit use?

- Existing national cancer datasets (linked to other health data) to support the audit.
- Data with the following information:
 - Age
 - Sex
 - Diagnosis date
 - Diagnosis site
 - Diagnosis type
 - Diagnosis stage
 - Diagnosis site
 - Diagnosis type
 - Diagnosis stage

How will the audit share findings with NHS organisations?

- Annual State of the Nation reports.
- Quarterly and ad-hoc reports to support ongoing work.

NAoMe Scoping Document published

The NAoMe Scoping Document was published on 30th November 2023 and includes:

- a review of key metastatic breast cancer clinical guidelines & relevant literature,
- results from the Scoping Survey carried out from February to April 2023,
- a summary of key findings from the National Audit of Breast Cancer in Older Patients (NABCOP), and
- a review of NABCOP and external performance indicators.

You can access the full report [here](#) and the executive summary (shown left) [here](#).

NAoMe presence at the COSD Roadshows

We are pleased to have been involved with the COSD (Cancer Outcomes and Services Dataset) Roadshows throughout January 2024. This has given us the opportunity to highlight key data considerations for the NAoMe.

There is still the opportunity to join the [February COSD Roadshows](#) (dates & locations via the link). We look forward to seeing you there!

You can access the NAoMe COSD leaflet (shown right) [here](#).

NAoMe COSD leaflet

The National Audit of Metastatic Breast Cancer (NAoMe) aims to report on patients diagnosed with metastatic breast cancer (MBC) who have been diagnosed, treated or managed in the UK (England, Wales, Northern Ireland, Scotland and Gibraltar) in 2023. The audit will focus on the quality of care and outcomes for these patients, with a particular emphasis on the use of systemic therapies and the management of symptoms and quality of life.

What are the priority areas for quality improvement?

- Improved data collection
- Improved data collection
- Improved data collection

What will the audit use?

- Existing national cancer datasets (linked to other health data) to support the audit.
- Data with the following information:
 - Age
 - Sex
 - Diagnosis date
 - Diagnosis site
 - Diagnosis type
 - Diagnosis stage
 - Diagnosis site
 - Diagnosis type
 - Diagnosis stage

How will the audit share findings with NHS organisations?

- Annual State of the Nation reports.
- Quarterly and ad-hoc reports to support ongoing work.

Other new publications

Since our last Newsletter in October 2023, we would like to share the following publications:

NAoMe Key Data Items – a crucial resource with a list of COSD data items of key importance for the NAoMe. Access this [here](#).

This includes **Cancer Recurrence data items**. It is important that recurrent cancers are recorded correctly through COSD. Patients with primary breast cancer which spreads to other parts of the body at a later date will be included in the NAoMe. We are currently working hard with COSD to improve the process of recording recurrence information.



NATCAN 1st Annual report this highlights the first year of progress for the 10 national cancer audits in England & Wales. It includes both breast cancer audits (NAoPri and NAoMe).

Read the full report [here](#).

NAoMe Patient & Public Involvement (PPI) Forum – recruitment in progress

The NAoMe Patient & Public Involvement Forum set-up meeting was held on 11th December 2023 to discuss and plan recruitment.

We are now recruiting for a diverse range of members (including people who have metastatic breast cancer, or who are a friend, family member or carer to a person who has metastatic breast cancer) for the NAoMe PPI Forum.



Follow us on X (formerly Twitter): [@NAoMe_news](https://twitter.com/NAoMe_news)

Email any breast audit-specific questions to: breastcanceraudits@rcseng.ac.uk